Amanat Acquisition Corp Class A Ordinary Shares(AMAN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$10.12
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for AMAN

11/13/2026: AMAN (1-star) is currently NOT-A-BUY. Pass it for now.

Amanat Acquisition Corp is a special purpose acquisition company formed to pursue business combinations within the healthcare and life sciences sectors. The company's primary strength lies in its experienced management team and its definitive agreement to merge with clinical-stage biopharmaceutical firm Corxel Pharmaceuticals. Its core investment story centers on gaining exposure to the high-growth obesity and cardiometabolic therapeutics market through a well-capitalized public vehicle. Key risks include clinical trial execution uncertainties, regulatory hurdles, and potential shareholder redemption pressures ahead of the merger. The stock suits speculative growth investors willing to monitor deal closing milestones and clinical development progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe stock offers potential growth exposure subject to the successful completion of the pending business combination with a clinical-stage biotech firm.
Momentum investorStrong fit while signal remains positivePrice momentum can fluctuate based on news flow surrounding the progress and shareholder approval of the pending Corxel Pharmaceuticals transaction.
Value investorMixed fitValuation is currently anchored near trust liquidation value, offering asset-backed safety but no fundamental earnings value yet.
Dividend investorWeak fitThe company pays no dividends and retains its capital exclusively for business combination activities.
Low-risk investorMixed fitWhile trust account protections limit immediate downside near cash value prior to a deal vote, post-combination execution risks remain high.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumShare prices can fluctuate around trust value depending on deal sentiment and broader market conditions.
Valuation riskMedium / highValuing a clinical-stage biopharmaceutical target involves substantial uncertainty regarding future clinical and commercial success.
Competition risk (biopharmaceutical and obesity therapeutics)HighThe incoming target faces intense competition from well-capitalized pharmaceutical companies developing obesity and cardiometabolic treatments.
Business qualityMediumThe underlying operating business depends heavily on clinical trial milestones rather than proven commercial revenue.
Dividend incomeLow / noneNo dividend yield is available to support income-focused strategies.
Execution riskHighThe company must successfully navigate regulatory clearances, shareholder votes, and clinical development pipelines to achieve its business objectives.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 97.87M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 104.4K shares
Beta -
52 Weeks Range 9.98 - 10.79
Updated Date 11/15/2026
52 Weeks Range 9.98 - 10.79
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -

Sector & Industry Intelligence

Sector

Financial Services

Constructive
Sentiment
Bullish
Momentum
BUY Breadth Improving
BUY participation
50.4%
Active BUY / eligible
61 / 121
30-Day BUY Count Change
+45
Market state
Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Shell Companies

BUY participation
100.0%
Active BUY / eligible
1 / 1
30-Day BUY Count Change
+1

Eligible universe: 1 stock.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Insufficient Data
PRICE PATH

Insufficient Data

The stock demonstrates a Insufficient Data price path pattern.

Insufficient Data
PRICE STABILITY

Insufficient Data

The stock price exhibits a Insufficient Data stability pattern.

Analysis of Past Performance

Type Stock
Historic Profit 0.66%
Avg. Invested days 34
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 5.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
AMAN receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
AMAN has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. Growth and ownership metrics are mixed: slightly negative earnings growth (+0.0%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
AMAN's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
AMAN's growth profile is soft, with the least-weak measure being revenue growth at +0.0% year over year. By comparison, while earnings growth (+0.0%, slightly negative) and free-cash-flow growth (+0.0%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 93.7% and approximately 0.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 3.85% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Nantahala Capital Management, LLC 24.81%
ADAR1 Capital Management LLC 7.75%
OZ Management LLC 7.57%
BRAIDWELL LP 7.24%
Great Point Partners LLC 5.17%

Unit Economics (Per $1K Revenue)

★★★★★
AMAN generates approximately $0 of gross profit, $0 of operating income, and $0 of free cash flow for every $1,000 of revenue. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 21.00%

Quantitative Style Profile

★★★★★
AMAN has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Trust Interest IncomeInterest earned on cash and marketable securities held in the designated trust account from IPO proceeds.The company does not generate commercial revenue and relies on financial interest earned on its escrowed cash reserves.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 96.24M
Price to Sales(TTM) -
Enterprise Value 96.24M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 7.80M
Shares Floating -
Shares Outstanding 7.80M
Shares Floating -
Percent Insiders 3.85
Percent Institutions 93.68

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.